根据上述有效接纳及申请的结果，补偿安排所涉及的未获认购股份及不合资格股东未售股份总数将为 6226万股供股股份。 新明中国(02699)发布公告，于2025年7月8日(星期二)下午四时正(即接纳最后时限)，已接获合共8份有效 申请，涉及合共1288.49万股供股股份，相当于供股项下所提呈发售供股股份总数约17.15%。 董事会谨此宣布，于2025年7月21日(星期一)下午四时正(即配售事项结束日期)，已成功根据配售事项向 不少于6名承配人配售6226万股未获认购股份，配售价为每股1.12港元，相等于认购价。因此，概无根 据配售事项可分派予不行动股东及不合资格股东的净收益。 ...

Group 1 - Company announced a placement and subscription agreement to sell 22.561 million existing shares, representing approximately 6.87% of the total issued shares as of the announcement date [1] - The purchase price is set at a discount of about 10.12% to the closing price of HKD 77.55 per share on the last trading day before the agreement [1] - The total expected proceeds from the placement and subscription are approximately HKD 1.573 billion, with net proceeds estimated at HKD 1.553 billion [2] Group 2 - The company plans to allocate 50% of the net proceeds for global research and development of pipeline products, 40% for commercialization efforts, and 10% for general administrative expenses [2] - The board believes that the placement and subscription provide an opportunity for further fundraising, which is beneficial for the long-term development of the group [2] - The initiative aims to attract long-term international institutional shareholders, enhance shareholder base, improve trading liquidity, and provide additional funding for drug pipeline development [2]

Group 1 - The company, Qizhi Group, announced a placement agreement to issue 3 million shares at a price of HKD 106.60 per share, representing approximately 1.14% of the existing issued shares [1] - The placement price reflects a discount of about 17.04% compared to the closing price of HKD 128.50 on the last trading day and a discount of approximately 17.44% compared to the average closing price of HKD 129.12 over the last five trading days [1] - The board believes that the placement will enhance the company's liquidity and financial position, expand the shareholder base, optimize the capital structure, and support sustainable development [1] Group 2 - If all placement shares are fully subscribed, the total gross proceeds are expected to be approximately HKD 320 million, with a net amount of about HKD 314 million after deducting commissions and related costs [2] - The net proceeds are planned to be used as follows: approximately 50% for domestic and international business operations, about 10% for research and development, and around 40% for optimizing the capital structure and other general corporate purposes [2] - The expected timeline for utilizing the net proceeds is by December 31, 2030, subject to adjustments based on future developments, market conditions, and business circumstances [2]

Group 1 - The company announced a share placement agreement involving its subsidiary, Sichuan Kelun Biotech Co., Ltd., to issue 5,918,000 H shares at a price of HKD 331.8 per share [1][2] - The net proceeds from the placement are expected to be HKD 1.943 billion, which will be used for product research and development, clinical trials, registration, manufacturing, commercialization, and enhancing internal R&D capabilities [1][2] - The completion of the placement is subject to certain conditions outlined in the placement agreement, indicating uncertainty regarding the timing and completion of the transaction [1] Group 2 - If the placement is successfully completed, the total shares of Kelun Biotech will change, with the company remaining the controlling shareholder with approximately 53.41% of the shares [2] - The placement aims to meet the funding needs for the continuous development and business growth of Kelun Biotech, thereby broadening its financing channels and positively impacting its operations and long-term development [2]

Group 1 - The company, Rongchang Biopharma (09995.HK), has entered into a placement agreement with Morgan Stanley and Huatai International to issue 19 million new H-shares at a placement price of HKD 42.44, which represents a discount of approximately 9.51% compared to the closing price of HKD 46.90 on May 21 [1] - The placement shares will account for about 10.02% of the existing issued H-shares and approximately 3.49% of the total issued shares as of the announcement date [1] - Assuming no other changes in the issued share capital, the placement shares will represent about 9.11% of the enlarged issued H-shares and approximately 3.37% of the total issued shares after the placement [1] Group 2 - The total estimated proceeds from the placement are approximately HKD 806 million, with net proceeds expected to be around HKD 796 million after deducting commissions and estimated expenses [2] - The company plans to use the net proceeds for the expansion of its core product, RC18, into key indications such as myasthenia gravis, membranous nephropathy, and for general corporate purposes [2]

Group 1 - The company, Wei Long Mei Wei (09985), has entered into a placement agreement to sell 80 million shares at a price of HKD 14.72 per share, which represents a discount of approximately 7.88% compared to the last closing price of HKD 15.98 [1][2] - The placement is expected to attract at least six professional or institutional investors, with no single investor anticipated to become a major shareholder post-placement [1] - The total expected gross proceeds from the placement and subscription are approximately HKD 1.178 billion, with net proceeds estimated at around HKD 1.167 billion after deducting commissions and estimated expenses [2] Group 2 - The funds raised from the placement and subscription are intended to enhance the company's financial strength, market competitiveness, and overall capabilities, promoting long-term sustainable development [2] - The placement and subscription are expected to enrich the company's shareholder base by attracting high-quality institutional investors and further improve the liquidity of the shares [2] - The board believes that the terms of the placement and subscription agreements are fair and reasonable, aligning with the best interests of the company and its shareholders [2]